TY - JOUR
T1 - ACCEPTABILITY OF PC-1005 GEL ADMINISTERED RECTALLY TO HIV-1 SERONEGATIVE ADULTS AT THREE DIFFERENT VOLUME LEVELS (MTN-037)
AU - The MTN-037 team
AU - Bauermeister, José A.
AU - Tingler, Ryan C.
AU - Ho, Ken
AU - Scheckter, Rachel
AU - McClure, Tara
AU - Davis, Jontraye
AU - Piper, Jeanna
AU - Friedland, Barbara A.
AU - Edick, Stacey
AU - Song, Mei
AU - Jiao, Yuqing
AU - Hendrix, Craig W.
AU - Hoesley, Craig
N1 - Publisher Copyright:
© 2022 The Guilford Press.
PY - 2022/8
Y1 - 2022/8
N2 - Multipurpose prevention technologies (MPT) have been increasingly researched for their dual-purpose preventative properties against HIV and other STIs. The acceptability of PC-1005, a topical MPT candidate, was explored among men and women participating in the MTN-037 Phase I trial at two U.S. sites (Pittsburgh, PA, and Birmingham, AL). We triangu-lated quantitative and qualitative assessments of the acceptability of three volumes (4 mL, 16 mL, 32 mL) of PC-1005 administered rectally (N = 12; 6 males, 6 females). Participants rated overall gel acceptability on a scale of 1–10, with a median of 7.17 (SD = 2.04) and had positive feelings about all three dose volumes, citing them to be very comfortable or comfortable (dose 1 = 91.7%; dose 2 = 91.7%; dose 3 = 83.3%). High acceptability of and comfort with all three dose volumes shows promise for PC-1005 as an MPT to prevent HIV and STIs, warranting future clinical development.
AB - Multipurpose prevention technologies (MPT) have been increasingly researched for their dual-purpose preventative properties against HIV and other STIs. The acceptability of PC-1005, a topical MPT candidate, was explored among men and women participating in the MTN-037 Phase I trial at two U.S. sites (Pittsburgh, PA, and Birmingham, AL). We triangu-lated quantitative and qualitative assessments of the acceptability of three volumes (4 mL, 16 mL, 32 mL) of PC-1005 administered rectally (N = 12; 6 males, 6 females). Participants rated overall gel acceptability on a scale of 1–10, with a median of 7.17 (SD = 2.04) and had positive feelings about all three dose volumes, citing them to be very comfortable or comfortable (dose 1 = 91.7%; dose 2 = 91.7%; dose 3 = 83.3%). High acceptability of and comfort with all three dose volumes shows promise for PC-1005 as an MPT to prevent HIV and STIs, warranting future clinical development.
KW - HIV prevention
KW - MPT
KW - microbicide
KW - rectal
KW - sexually transmitted infections
UR - http://www.scopus.com/inward/record.url?scp=85136233073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136233073&partnerID=8YFLogxK
U2 - 10.1521/aeap.2022.34.4.257
DO - 10.1521/aeap.2022.34.4.257
M3 - Article
C2 - 35994578
AN - SCOPUS:85136233073
SN - 0899-9546
VL - 34
SP - 257
EP - 271
JO - AIDS Education and Prevention
JF - AIDS Education and Prevention
IS - 4
ER -